ArticleGastroenterology research and practice2025
QingXia HuaYu Formula Alleviates Severe Acute Pancreatitis-Associated Intestinal Injury by Modulating Group 3 Innate Lymphoid Cells.
Article in Gastroenterology research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe acute pancreatitis (SAP), one of the common causes of acute abdomen in clinical practice, is characterized by acute and rapid onset as well as the systemic inflammatory response syndrome, which often leads to intestinal injury and high mortality. Recent studies indicate that innate lymphoid cells (ILCs) play an important role in the connection of SAP and intestinal injury. TCM, including the QingXia HuaYu (QXHY) formula, is known to benefit gastrointestinal dysfunction in SAP, but its mechanisms, especially regarding ILCs, are unclear. Methods: A mouse model of SAP was established by retrograde infusion of sodium taurocholate into the common bile duct of C57BL/6 mice. QXHY was orally administered three times postinfusion. Serum inflammatory markers, pancreatic myeloperoxidase, and histopathological changes in the mice with SAP with or without QXHY treatment were used to evaluate the pancreatic injury and the therapeutic effects of QXHY. Intestinal tight junctions, serum markers for mucosal injury, and inflammatory factors were used to analyze the effects of QXHY on intestinal injury in SAP mice. Flow cytometry and qRT-PCR were used to analyze ILC3s numbers and functions. Results: QXHY significantly reduced serum amylase, pancreatic myeloperoxidase, and improved histopathological manifestations in SAP mice. In addition, QXHY reduced intestinal damage, improved tight junction integrity, and lowered proinflammatory cytokines. Mechanistically, QXHY restored the diminished ROR Conclusion: QXHY mitigates SAP-associated intestinal damage by enhancing ILC3 cells to regulate tissue injury and maintain homeostasis. Our data suggest that QXHY is a promising alternative and cost-friendly therapy for SAP-associated intestinal damage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.